Home > Boards > US Listed > Medical - Healthcare > Pfenex Inc. (PFNX)

Pfenex Inc. is a clinical-stage biotechnology company. The

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 630
Posts 41,131
Boards Moderated 6
Alias Born 12/12/04
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 5/11/2020 4:56:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 5:07:02 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/7/2020 5:04:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2020 4:16:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 4:09:21 PM
Pfenex Reports First Quarter 2020 Results and Provides Business Update GlobeNewswire Inc. - 5/7/2020 4:05:10 PM
Pfenex to Announce First Quarter 2020 Financial Results on May 7 GlobeNewswire Inc. - 4/24/2020 4:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 8:01:41 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/14/2020 5:18:23 PM
Pfenex Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 T... GlobeNewswire Inc. - 4/14/2020 5:04:52 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 4/14/2020 11:01:26 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 4/10/2020 4:33:26 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/1/2020 4:55:51 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/11/2020 4:33:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/11/2020 4:13:10 PM
Pfenex Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update GlobeNewswire Inc. - 3/11/2020 4:05:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/3/2020 6:05:21 PM
Pfenex to Announce Fourth Quarter and Year-End 2019 Financial Results on March 11 GlobeNewswire Inc. - 2/26/2020 5:03:26 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 6:01:05 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2020 2:51:36 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 2:51:20 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 2:45:05 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 12:18:01 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/4/2020 8:01:46 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/16/2020 4:18:20 PM
crudeoil24 Member Level  Saturday, 02/13/16 09:47:42 AM
Re: BrazenBull post# 4
Post # of 49 
Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The Company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). The Company is conducting a Phase Ib/IIa trial for PF582 in patients with wet age-related macular degeneration (wet AMD). The Company's next most advanced product candidate is PF530, a biosimilar candidate to Betaseron (interferon beta-1b). The Company's pipeline includes five other preclinical biosimilar products under development, such as PF726, PF529, PF688, PF694 and PF444. It is also developing a vaccine Px563L, which is an anthrax vaccine candidate; a generic product PF708, and next generation biologic candidates. The Company's product candidates are enabled by its patented protein production platform, Pfenex Expression Technology.

http://www.pfenex.com


DUKE BASKETBALL and NOTRE DAME FOOTBALL
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist